Last reviewed · How we verify
hUC-MSC
At a glance
| Generic name | hUC-MSC |
|---|---|
| Also known as | BX-U001 |
| Sponsor | Guangzhou Women and Children's Medical Center |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss (PHASE1, PHASE2)
- Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma (NA)
- Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke (PHASE1)
- Intracochlear Application of VSF1.01 for the Reduction of Cochlear Implant Surgery Related Trauma (PHASE1, PHASE2)
- Safety and Efficacy of hUC-MSC for the Treatment of Cartilage Damage in the Knee Joint (PHASE1, PHASE2)
- BC-101 in Treatment of Nasolabial Fold Wrinkles (PHASE1)
- Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS (PHASE1, PHASE2)
- Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid Arthritis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hUC-MSC CI brief — competitive landscape report
- hUC-MSC updates RSS · CI watch RSS
- Guangzhou Women and Children's Medical Center portfolio CI